214 related articles for article (PubMed ID: 38593781)
41. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
[TBL] [Abstract][Full Text] [Related]
42. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
[TBL] [Abstract][Full Text] [Related]
43. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P
Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922
[TBL] [Abstract][Full Text] [Related]
44. An acute lymphoblastic leukemia cell-based preclinical assay revealed functional differences between commercial brands of L-asparaginase administered in Colombia.
Rincón Reyes DF; Padilla Agudelo JL; Pinilla da Silva AI; Ortega Quintero DM; Valencia Libreros DL; Contreras Acosta AD; Gutiérrez Triana JA
Pediatr Blood Cancer; 2023 Apr; 70(4):e30199. PubMed ID: 36633223
[TBL] [Abstract][Full Text] [Related]
45. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.
Richter A; Fischer E; Holz C; Schulze J; Lange S; Sekora A; Knuebel G; Henze L; Roolf C; Murua Escobar H; Junghanss C
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803402
[TBL] [Abstract][Full Text] [Related]
46. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.
Goodman PA; Wood CM; Vassilev A; Mao C; Uckun FM
Oncogene; 2001 Jul; 20(30):3969-78. PubMed ID: 11494125
[TBL] [Abstract][Full Text] [Related]
47. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
Kruth KA; Fang M; Shelton DN; Abu-Halawa O; Mahling R; Yang H; Weissman JS; Loh ML; Müschen M; Tasian SK; Bassik MC; Kampmann M; Pufall MA
Blood; 2017 Jun; 129(22):3000-3008. PubMed ID: 28424165
[TBL] [Abstract][Full Text] [Related]
48. Asparaginase in acute lymphoblastic leukemia.
Kawedia JD; Rytting ME
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S14-7. PubMed ID: 25486949
[TBL] [Abstract][Full Text] [Related]
49. Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis.
Göpel W; Schnetzke U; Hochhaus A; Scholl S
Ann Hematol; 2016 Oct; 95(11):1899-901. PubMed ID: 27488287
[No Abstract] [Full Text] [Related]
50. Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.
Chien WW; Le Beux C; Rachinel N; Julien M; Lacroix CE; Allas S; Sahakian P; Cornut-Thibaut A; Lionnard L; Kucharczak J; Aouacheria A; Abribat T; Salles G
Sci Rep; 2015 Jan; 5():8068. PubMed ID: 25626693
[TBL] [Abstract][Full Text] [Related]
51. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
52. p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.
Davies C; Hogarth LA; Mackenzie KL; Hall AG; Lock RB
Cell Cycle; 2015; 14(22):3602-12. PubMed ID: 26506264
[TBL] [Abstract][Full Text] [Related]
53. Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia.
Sarno J; Domizi P; Liu Y; Merchant M; Pedersen CB; Jedoui D; Jager A; Nolan GP; Gaipa G; Bendall SC; Bava FA; Davis KL
Nat Commun; 2023 May; 14(1):2935. PubMed ID: 37217509
[TBL] [Abstract][Full Text] [Related]
54. [Cerebral thrombosis in a child with acute lymphocytic leukemia during L-asparaginase therapy].
Horigome Y; Hanada T; Inudoh M; Takita H
Rinsho Ketsueki; 1989 Aug; 30(8):1284-8. PubMed ID: 2601047
[TBL] [Abstract][Full Text] [Related]
55. Time Course and Management of Protracted Anaphylaxis Due to PEG-Asparaginase.
Fertal SA; Bradeen HA; Friesen E; Heath JL
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e385-e387. PubMed ID: 32815880
[TBL] [Abstract][Full Text] [Related]
56. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
Kashanian SM; Holtzman NG; Patzke CL; Cornu J; Duffy A; Koka M; Niyongere S; Duong VH; Baer MR; Apata J; Kamangar F; Emadi A
Cancer Chemother Pharmacol; 2021 Jun; 87(6):817-826. PubMed ID: 33677674
[TBL] [Abstract][Full Text] [Related]
57. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.
Bertaina A; Vinti L; Strocchio L; Gaspari S; Caruso R; Algeri M; Coletti V; Gurnari C; Romano M; Cefalo MG; Girardi K; Trevisan V; Bertaina V; Merli P; Locatelli F
Br J Haematol; 2017 Feb; 176(4):629-636. PubMed ID: 28116786
[TBL] [Abstract][Full Text] [Related]
58. Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia.
Stams WA; den Boer ML; Beverloo HB; Kazemier KM; van Wering ER; Janka-Schaub GE; Pieters R
Haematologica; 2005 Dec; 90(12):1697-9. PubMed ID: 16330447
[TBL] [Abstract][Full Text] [Related]
59. A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.
Chen SH; Yang W; Fan Y; Stocco G; Crews KR; Yang JJ; Paugh SW; Pui CH; Evans WE; Relling MV
Leukemia; 2011 Jan; 25(1):66-74. PubMed ID: 21072045
[TBL] [Abstract][Full Text] [Related]
60. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia.
Asselin BL; Kreissman S; Coppola DJ; Bernal SD; Leavitt PR; Gelber RD; Sallan SE; Cohen HJ
J Pediatr Hematol Oncol; 1999; 21(1):6-12. PubMed ID: 10029805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
